Malignancy Risk Assessment, Pelvic Mass, OVA1 Plus
Also known as: OVA1 PLUS
Use
The Malignancy Risk Assessment, Pelvic Mass, OVA1 Plus test is designed to assess the risk of ovarian cancer in women presenting with an adnexal mass. This test combines the analysis of multiple biomarkers to provide a comprehensive risk assessment, aiding in the management and decision-making process for patients with pelvic masses suspicious for malignancy.
Special Instructions
Not provided.
Limitations
The test is performed by a non-ARUP laboratory and should be interpreted within the context of clinical findings and other test results. The presence of interference from other substances or conditions that may affect the accuracy of biomarker measurement is a potential limitation. The stability of the specimen should be maintained, and specimens that do not meet the stability criteria or volume requirements are at risk of rejection.
New York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 10334-1 - Cancer Ag125 SerPl-aCnc
- 11502-2 - Laboratory report
Result Turnaround Time
4-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.2 mL
Minimum Volume
1.1 mL
Container
ARUP standard transport tube
Collection Instructions
Collect from a serum separator tube (SST). Transfer to an ARUP standard transport tube.
Patient Preparation
Testing should not be performed on patients 17 years of age or younger.
Storage Instructions
Store and transport the specimen frozen. Refrigerated storage is also acceptable.
Causes for Rejection
Specimens not meeting the stability requirements or improperly stored.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 8 days |
| Frozen | 9 weeks |
Other tests from different labs that may be relevant